US20180169187A1 - Compositions and methods for the treatment of malnutrition - Google Patents

Compositions and methods for the treatment of malnutrition Download PDF

Info

Publication number
US20180169187A1
US20180169187A1 US15/738,215 US201615738215A US2018169187A1 US 20180169187 A1 US20180169187 A1 US 20180169187A1 US 201615738215 A US201615738215 A US 201615738215A US 2018169187 A1 US2018169187 A1 US 2018169187A1
Authority
US
United States
Prior art keywords
liquid
semi
malnutrition
nutritional composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/738,215
Other languages
English (en)
Inventor
Gerben Carolus Martinus ZONDAG
Reinder STRIJKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitalnext BV
Original Assignee
Vitalnext BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56345097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20180169187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vitalnext BV filed Critical Vitalnext BV
Assigned to VITALNEXT B.V. reassignment VITALNEXT B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STRIJKER, Reinder, ZONDAG, Gerben Carolus Martinus
Publication of US20180169187A1 publication Critical patent/US20180169187A1/en
Priority to US16/906,541 priority Critical patent/US11419915B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to the field of medicine and nutrition. More in particular, the invention relates to means and methods for the treatment of malnutrition that may be the result of a disease.
  • the invention further relates to nutritional compositions for enteral administration, and supplements, and particular combinations of compounds in such nutritional compositions and supplements, to treat patients suffering from malnutrition and complications related thereto, such as loss of body weight and muscle atrophy.
  • Adequate nutrition is also important for preserving gastro-intestinal function: chronic malnutrition results in changes in pancreatic and bladder exocrine functions, intestinal blood flow, villous architecture and intestinal permeability.
  • the colon loses its ability to reabsorb water and electrolytes, and secretion of ions and fluid occurs in the small and large bowel. This may result in diarrhea, which is associated with an even higher mortality rate in already weakened, malnourished patients.
  • One of the objects of the invention is to provide new nutritional compositions that may be used to treat malnutrition and that cause increase in body weight and/or reverse the devastating effects of muscle atrophy, wherein such compositions are tested in scientific sound experiments and conclusions in respect of their effects are based on significant scientific data.
  • a first aspect of the invention provides a liquid or semi-liquid nutritional composition
  • a liquid or semi-liquid nutritional composition comprising: 70 to 200 mg/ml dairy proteins, 30 to 45 ng/ml vitamin D or a derivative thereof; and 0.2 to 0.8 mg/ml ursolic acid; wherein the casein:whey ratio in said dairy proteins ranges from 20:80 to 80:20 and wherein 30 to 45% of the total amino acid content is a mixture of leucine, isoleucine and valine.
  • the casein:whey ratio is about 60:40, and/or composition of the invention is substantially free of other proteins besides casein and whey, and/or the concentration dairy proteins is about 100 mg/ml, and/or the concentration ursolic acid is about 0.35 mg/ml, and/or the concentration vitamin D or a derivative thereof is about 37.5 ng/ml.
  • the invention also relates to a liquid or semi-liquid nutritional composition
  • a liquid or semi-liquid nutritional composition comprising the constituents with their respective concentrations as listed in Table II as disclosed herein, and further comprising 0.2 to 0.8 mg/ml ursolic acid.
  • the invention also relates to a powder formulation comprising dairy proteins, vitamin D or a derivative thereof, ursolic acid and optionally an amino acid premix comprising free leucine, free isoleucine and free valine; all in suitable amounts that, when combined with a suitable carrier (such as water or another appropriate liquid or semi-liquid carrier), yields a liquid or semi-liquid nutritional composition according to the invention.
  • a suitable carrier such as water or another appropriate liquid or semi-liquid carrier
  • the invention relates to a powder formulation comprising an amino acid premix comprising free leucine, free isoleucine and free valine; vitamin D or a derivative thereof; and ursolic acid; all in suitable amounts that, when combined with a dairy protein-containing product, such as milk, quark, butter, yoghurt, etc. yields a liquid or semi-liquid nutritional composition according to the invention.
  • the invention also relates to a liquid or semi-liquid nutritional composition according to the invention, or a dry powder formulation according to the invention, for use in the treatment of a patient suffering from malnutrition, weight loss and/or muscle atrophy.
  • malnutrition in this case preferably refers to under-nutrition.
  • the invention also relates to a powder formulation according to the invention in the manufacture of a medicament for the treatment of malnutrition, weight loss and/or muscle atrophy.
  • FIG. 1 shows the schematic outline of the study design of the starvation-refeeding experiment of example 1.
  • animals were provided with a restricted diet (60% of normal daily intake) for a certain amount of time (starvation phase) to induce a state of malnutrition, in which the animals had lost approximately 25% of their bodyweight.
  • restricted diets were supplemented with either regular mouse feed (“chow”) up to their normal (100%) intake levels, or with equivalent amounts of the existing medical nutrition product Nutridrink Compact Protein (Nutridrink CP, Nutricia, the Netherlands) or the novel composition of the present invention, referred to as Vital01.
  • Non-starved animals maintained on a regular 100% chow diet served as control group for this study.
  • animals in Group 3 were sacrificed on day 14 at the end of the starvation period.
  • FIG. 2 shows the decline in total body weight of the mice, averaged for all animals in Groups 3-6 (that were maintained on the 60 kcal % diet for two weeks) in comparison to non-starved animals in control Group 2 (receiving their regular, daily 100 kcal % intake). On day 13 the mice had lost approximately 25% of their total body weight in all starvation groups. Shown is also that this weight loss was significant (P value ⁇ 0.05).
  • FIG. 3 shows the effect on total body weight (in grams) after refeeding with normal amounts of standard mouse feed (Ssniff R/M diet, 100% chow control), and the novel composition of the present invention, referred to as Vital01.
  • the commercially available and widely prescribed Nutridrink CP formulation was provided to one group of animals. Surprisingly, and exceeding the initial expectations of the investigators, the animals receiving Vital01 gained body weight much faster than was anticipated.
  • FIG. 4 shows the effects on Lean body mass (in grams) after refeeding with normal 100% chow (control), and the compositions Nutridrink CP and Vital01. Again, the Vital01 composition refeeding resulted in a faster gain of lean body mass in comparison to the Nutridrink CP and 100% chow control.
  • FIG. 5 is a bar diagram showing the mass (in grams) of the quadriceps muscle after refeeding and sacrifice.
  • the bars represent (from left to right): the chow baseline, the muscle wasting group, the control 100% chow refed group, the Nutridrink CP group and the Vital01 group.
  • the increase in mass observed in all refeeding groups was significant in relation to the muscle wasting group whereas only for the Vital01 group, the increase in quadriceps mass observed was significant in comparison to the chow 100% control group.
  • FIG. 6 is a bar diagram showing the mass (in grams) of the gastrocnemius muscle after sacrifice and after refeeding.
  • the bars represent (from left to right): the chow baseline, the muscle wasting group, the control 100% chow refed group, the Nutridrink CP group and the Vital01 group.
  • the increase in mass observed in all refeeding groups was significant in relation to the muscle wasting group whereas the increase in gastrocnemius mass observed in the Vital01 group was significant in comparison to the chow 100% control group and to the Nutridrink CP group.
  • FIG. 7 is a bar diagram showing the mass (in grams) of the soleus muscle after sacrifice and after refeeding.
  • the bars represent (from left to right): the chow baseline, the muscle wasting group, the control 100% chow refed group, the Nutridrink CP group and the Vital01 group. No significant difference in mass of this particular muscle was observed between the different refeeding groups. The mass of the muscle returned to normal levels after refeeding in all refeeding groups.
  • FIG. 8 is a bar diagram showing the mass (in grams) of the tibialis muscle after sacrifice and after refeeding.
  • the bars represent (from left to right): the chow baseline, the muscle wasting group, the control 100% chow refed group, the Nutridrink CP group and the Vital01 group. Although the increase in mass in the Nutridrink CP and Vital01 groups versus the 100% chow control group was measured, no significant difference in mass of this particular muscle was observed between the different refeeding groups.
  • FIG. 9 is a bar diagram showing the mass (in grams) of the liver after sacrifice and after refeeding.
  • the bars represent (from left to right): the chow baseline, the muscle wasting group, the control 100% chow refed group, the Nutridrink CP group and the Vital01 group.
  • the liver had lost a significant mass upon starvation and regained mass upon refeeding in all refeeding groups, reaching almost normal levels just before sacrifice. No difference in increase in liver mass was observed between the different refeeding groups.
  • FIG. 10 shows the statistic calculations for differences between groups in bodyweight and in muscle weight in SPSS using a non-parametric Kruskall-Wallis test followed by Mann-Whitney.
  • FIG. 11 shows the statistic calculations employed for muscle mass measurements in all groups. It is important to stress that the increase in muscle mass in animals treated with Vital01 is significantly better than the comparator Nutridrink CP (indicated in the table by an asterisk).
  • Good nutrition is a vital part of care.
  • Good nutritional care encompasses nutritional screening to identify patients at nutritional risk, and care planning to ensure that patients receive the right nutrition, at the right time.
  • Nutritional intervention takes many forms from providing appetizing, nutritious food, to helping people eat and drink to providing tailored artificial nutrition support.
  • ‘Malnutrition’ as used herein is defined as a state of nutrition in which a deficiency, excess or imbalance of energy, protein, and other nutrients causes measurable adverse effects on tissue/body form (body shape, size and composition), function, and clinical outcome.
  • this definition in general relates both to over-nutrition (overweight/obesity) and under-nutrition, the methods and means of the present invention predominantly and most preferably are applied to treat under-nutrition.
  • malnutrition as used herein refers to under-nutrition.
  • Malnutrition further encompasses the additional concept of nutritional risk, reflecting common practice whereby these terms are often used interchangeably.
  • Medical nutrition is a term used to describe (commercially) available products for nutritional support, including oral nutritional supplements (ONS, see definition below), enteral tube feeds and parenteral nutrition.
  • Medical nutrition fulfills the patient's nutritional requirements that are generally not met by the normal diet. It influences the immunological, biochemical, and metabolic status of the patient and thereby provides significant clinical benefits.
  • ONS use food-based ingredients with well-established safety records, and are in accordance to the European FSMP guidelines (Foods for Special Medical Purposes).
  • Enteral nutrition as used herein generally refers to any method of feeding that uses the gastrointestinal tract to deliver part or all of a person's caloric and nutrient requirements. It can include a normal oral diet, the use of oral nutritional supplements or delivery of part or all of the daily requirements through tube feeding via different routes such as nasoenteric, nasogastric, nasoduodenal, nasojejunal, rectal or through percutaneous tubes.
  • Nutrition assessment refers to a detailed, more specific and in-depth evaluation of a patient's nutritional state, typically by an individual/clinician with nutritional expertise (e.g. a dietitian, clinician studying nutrition, or a nutrition nurse specialist) or by a nutritional support team. This will usually be conducted in the case of nutritional problems identified by the screening process or when there is uncertainty about the appropriate course of action.
  • the assessment process allows more specific nutritional care plans to be developed for the individual patient.
  • nutritional assessment includes the assessment of the patient's state or risk in respect of muscle atrophy, for which specified treatments may be required.
  • Indicative of a malnutrition are for instance the occurrence of a low body mass index (BMI), unintentional weight loss, loss of appetite and food intake that appears insufficient to meet the average and normal requirements. Poor muscle strength and/or atrophy are also indicative for malnutrition or for nutritional intervention.
  • BMI body mass index
  • Nutritional screening is a rapid, simple and general procedure used by nursing, medical or other staff, to detect those at risk of suffering from nutritional problems, so that action can be taken, preferably by administering the compositions of the present invention, or in another aspect, by providing the treatment methods as disclosed herein. Screening should generally be repeated at intervals.
  • Nutritional support generally refers to support that includes food, ONS (such as those of the present invention), tube feeding and parenteral nutrition.
  • ONS are multi-nutrient liquid, semi-solid, semi-liquid or powder products (that may be dissolved to form a (semi-)liquid) that provide macronutrients and micronutrients, preferably with the aim of increasing oral nutritional intake and that add to the treatment of disorders, which have resulted from malnutrition (under-nutrition).
  • ONS are nutritionally complete and could preferably also be used as a sole source of nutrition.
  • ONS are distinct from dietary supplements that provide vitamins, minerals and/or trace elements in a pill format (also known as food supplements).
  • nutritional compositions of the present invention may comprise compounds and agents that are (or may be) present in certain and generally available dietary- and food supplements.
  • a compound that is often administered as an ingredient of a dietary supplement or in a food-supplement does not make the nutritional compositions of the present invention a dietary supplement or a food supplement.
  • a liquid or semi-liquid nutritional composition according to the invention can be administered via enteral routes, preferably orally, and in a suitable form, perhaps even at the patient's request in a form that the patient prefers.
  • ONS is an effective strategy for the management of malnutrition in hospitalized patients, older people and people who are undernourished. It has been shown to improve nutritional intake, increase or attenuate weight loss and improve function or activities of daily living. Nevertheless, it has also been found that the intake of ONS suffer from poor adherence (also referred to as ‘compliance’), a term used to describe how well a patient is following the advice or treatment plan. Reasons for such poor adherence are varied. For instance, many medical nutrition formulations are simply tasteless or have a taste that is considered as ‘bad’ by many. Another aspect adding to poor compliance is slow gastric emptying and the high level of satiety that individuals experience after taking a serving of currently available medical nutrition formulations.
  • muscle atrophy A well-known result of being bedridden for prolonged period of time is muscle decay, the wasting of muscle, generally referred to as ‘muscle atrophy’. Starvation (severe malnutrition) and disuse of muscles eventually always leads to muscle atrophy. Hence, although a patient may or may not have proper nutritional intake, the fact that the patient is bedridden and is unable to exercise sufficiently, may result in- and will certainly add to the appearance of muscle atrophy.
  • the present invention provides methods and means to counteract and/or prevent muscle atrophy, either due to malnutrition, and/or due to prolonged disuse of muscles, for instance in the case of patients that need to stay in bed and cannot use their muscles sufficiently.
  • the nutritional compositions of the present invention have a protein composition that generally ensures a more rapid release from the stomach than products known in the art, predominantly due to the high whey content.
  • High casein content makes that under low pH circumstances, such as in the stomach, the product hardens and precipitates.
  • the relative higher abundance of whey protein in the nutritional compositions of the present invention causes a lower precipitation in the stomach and a more rapid entry into the gut. This effect makes that people tend to feel less ‘full’ after taking the nutritional compositions of the present invention, as compared to nutritional supplements from the art that have a high casein content and a low whey content. Feeling less ‘full’ ensures a better compliance.
  • Muscle atrophy is a widely known and widespread disorder. Compositions that counteract muscle atrophy are known. For instance, US 2006/0035824 (A1) discloses the administration of gOBG3, thereby accelerating the reorganization and differentiation of muscle cells, and thereby treating the muscle disorder.
  • the present invention relates to a composition that appears unique and highly beneficial in the treatment of weight loss and malnutrition-related muscle atrophy, when compared to the ONS known in the art.
  • ursolic acid with the chemical formula C 30 H 48 O 3 , which is sometimes referred to as urson, prunol, malol, 3-3-hydroxy-urs-12-ene-28-oic acid or 3-beta-3-hydroxy-urs-12-ene-28-oic-acid.
  • Ursolic acid belongs to the family of pentacyclic triterpenoids that also includes its isomers like oleanolic acid, and all of its natural occurring analogs and derivatives such as glycosides. It is found in many herbs, plants and fruits, such as basil, cranberries, and rosemary. Especially apple peels contain relatively high quantities of ursolic acid. As such, ursolic acid in low concentrations can be considered a common constituent of the human diet. Ursolic acid has been ascribed several roles including anti-tumor effects by inhibiting the STAT3 activation pathway. It is thought to prevent cancer cell proliferation and induce apoptosis.
  • Ursolic acid has also been found to inhibit JNK expression and IL-2 activation of Jurkat leukemic T cells leading to the reduction of proliferation and T cell activation.
  • the use of ursolic acid for the treatment of muscle atrophy has been suggested (Kunkel S D et al. 2011. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 13(6):627-638).
  • WO 2012/170546 discloses the use of at least seven compound classes including thousands of derivatives thereof to treat muscle atrophy.
  • Ursolic acid has also been disclosed for use against Alzheimer's disease (U.S. Pat. No. 8,021,701).
  • compositions of the present invention have a casein to whey protein ratio ranging from 20:80 to 80:20.
  • Nutridrink CP (as shown in the examples) has a casein to whey ratio of approximately 93:7.
  • all protein in the compositions of the present invention are dairy proteins.
  • the dairy casein and whey proteins may be supplemented with protein from other animal or plant sources.
  • the term ‘casein’ as used herein refers both to caseinate and micellar casein.
  • the caseinate may be sodium-caseinate, calcium-caseinate, magnesium-caseinate, or potassium-caseinate.
  • the caseinate is calcium-caseinate or sodium-caseinate.
  • Whey protein is a superior class of food protein.
  • Whey protein has a good amino acid profile and it is known to increase protein synthesis in mammals (due to its high leucine content). Whey protein is well-tolerated and as mentioned above, it ensures increased gastric emptying. Moreover, whey protein has bioactive proteins with immune enhancing properties (lactoglobulins, ⁇ -lactalbumin, immunoglobulins, lysozyme, and lactoferrins).
  • the present invention relates to a liquid or semi-liquid nutritional composition
  • a liquid or semi-liquid nutritional composition comprising: 70 to 200 mg/ml dairy proteins; 30 to 45 ng/ml vitamin D or a derivative thereof; and 0.2 to 0.8 mg/ml ursolic acid; wherein the casein:whey ratio in said dairy proteins ranges from 20:80 to 80:20 and wherein 30 to 45% of the total amino acid content is a mixture of leucine, isoleucine and valine.
  • the casein:whey ratio in said liquid or semi-liquid nutritional composition is about 60:40, and/or the concentration dairy proteins is about 100 mg/ml, and/or the concentration ursolic acid is about 0.35 mg/ml.
  • the amount of dairy proteins that was used was approximately 10.56 g/100 ml, which includes a small percentage of fat.
  • the preferred amount of dairy proteins is set at 100 mg/ml.
  • the amount of dairy proteins may range between 70 to 200 mg/ml in the composition to yield good results in the treatment of malnutrition, weight loss and/or muscle atrophy.
  • the composition is substantially free of other proteins besides casein and whey. This means that in a preferred aspect of the present invention the casein protein+whey protein adds up to 100% of the protein amount. For example, when the amount of protein from casein is 60%, then the remainder of the protein content is preferably 40%, all from whey protein.
  • the nutritional compositions of the invention preferably comprises a mixture of free branched-chain amino acid selected from the group consisting of leucine, isoleucine and valine. These amino acids are the only three branched-chain proteinogenic amino acids present in nature, and all three are essential amino acids for humans. However, in the event that sufficient dairy proteins are present in the composition of the present invention in which 30-45% of the total amino acid content in said composition is made up of a mixture of leucine, isoleucine and valine, no additional (free) amino acids of these types are required. However, when the dairy protein content is such that the range of 30-45% of these essential amino acid mix is not reached, free amino acids of this type will be added, preferably in a premix.
  • the invention relates to a liquid or semi-liquid nutritional composition according to the invention, comprising valine and isoleucine both in a concentration of 7 to 10% of the total amino acid content and leucine in a concentration of 16 to 25% of the total amino acid content, and wherein valine, isoleucine and leucine are present in both free and bound form.
  • the liquid or semi-liquid nutritional composition of the present invention also comprises Vitamin D, preferably in a concentration of about 37.5 ng/ml. It is known in the art that there are two types of Vitamin D, both considered herein as ‘derivatives of Vitamin D’: Vitamin D2 and Vitamin D3, which may both (solely or in combination) be part of the nutritional composition of the present invention. Preferably Vitamin D3 is used.
  • the present invention relates to a powder that, when dissolved in a suitable solvent, forms a liquid or semi-liquid composition suitable for enteral, preferably oral, administration, and wherein the amounts of the constituents in the powder are such that the correct amounts of ingredients are generated and that, preferably, a 1 ⁇ 6 daily dose is generated.
  • the invention also relates to a powder formulation comprising dairy proteins, vitamin D or a derivative thereof, ursolic acid; and optionally an amino acid premix comprising free leucine, free isoleucine and free valine; all in suitable amounts that, when combined with a suitable carrier, yields a liquid or semi-liquid nutritional composition according to the invention.
  • the invention relates to a powder formulation comprising an amino acid premix comprising free leucine, free isoleucine and free valine, vitamin D or a derivative thereof; and ursolic acid; all in suitable amounts that, when combined with a dairy protein-containing product, such as milk, buttermilk, quark or yoghurt, yields a liquid or semi-liquid nutritional composition according to the invention.
  • the powder formulation of the present invention is ‘substantially dry’, which means that trace amounts of liquid (from the air or otherwise) may be present, but that the powder is free-flowing and in principle suitable for handling, dissolving, transportation and/or (long-term) storage.
  • the liquid or semi-liquid composition of the present invention is a dose of 100 ml wherein the compounds are dissolved or dispersed or taken up, preferably by a single dispersion of a powder according to the present invention in a suitable solvent to finally yield a nutritional composition according to the present invention.
  • a 100 ml dose is suitable for oral administration and is generally suitable as a 1 ⁇ 6 daily dose.
  • the liquid in which the powder of the present invention is dissolved is water.
  • the powder of the present invention comes in packages that can easily be used for dissolving the powder in a solvent.
  • the powder of the present invention may or may not contain dairy proteins as the required dairy proteins come from the solvent in which the powder is dissolved.
  • the result will be a liquid or semi-liquid nutritional composition according to the invention.
  • the powder of the present invention may lack dairy proteins, or may contain dairy proteins in such suitable amounts that the resultant is a liquid or semi-liquid nutritional composition according to the present invention and as used and disclosed herein.
  • the skilled person would be able to determine the amount of dairy proteins such as casein and whey, determine their ratio, and based on that, determine the amount of dairy proteins to be added to the powder to achieve the correct amounts of dairy proteins when a liquid or semi-liquid nutritional composition according to the present invention is wanted.
  • concentrations of the essential amino acids leucine, isoleucine and valine that may be present (all) in the dairy proteins, but that may also be added as free amino acids to reach the concentrations of the compositions of the present invention.
  • the invention relates to liquid or semi-liquid nutritional composition
  • liquid or semi-liquid nutritional composition comprising the constituents with their respective concentrations as listed in Table II and further comprising 0.2 to 0.8 mg/ml ursolic acid.
  • the amounts are generally dissolved to form a liquid or semi-liquid for enteral administration.
  • the amounts of Table II together with the suitable amounts of ursolic acid are dissolved to form a liquid or semi-liquid for enteral administration of about 100 ml, which is approximately 1 ⁇ 6 of daily portion to treat malnutrition, weight loss and/or muscle atrophy.
  • it is preferred for this composition that the nutritional compositions of the present invention are held in a substantially dry state, such as a powder formulation.
  • the nutritional composition according to the invention is a substantially dry powder for dissolving it in a suitable solvent, preferably water (in which case the powder contains dairy proteins in the suitable concentrations).
  • a suitable solvent preferably water (in which case the powder contains dairy proteins in the suitable concentrations).
  • the nutritional composition of the present invention when available in powder form, is preferably dissolved, dispersed, or mixed in a suitable carrier such as water, tea, fruit or vegetable juice, a suitable buffer, gel, pudding or yoghurt to obtain a substance that can easily be administered via drinking or for instance via tube-feeding.
  • a suitable carrier such as water, tea, fruit or vegetable juice, a suitable buffer, gel, pudding or yoghurt to obtain a substance that can easily be administered via drinking or for instance via tube-feeding.
  • a suitable carrier may be selected by a user or consumer based on personal preference and may contain intrinsic amounts of protein, vitamins or other ingredients which are not accounted for in Table II.
  • the present invention in another embodiment, also relates to a liquid or semi-liquid composition for oral delivery in which the powder of the present invention is dissolved.
  • Dissolving the powder formulation of the present invention may occur any time before consumption, such as directly before or before the composition is offered in a container such as a bottle or a tube, as long as it does not go off or gets rotten.
  • the invention relates to a liquid or semi-liquid nutritional composition according to the invention, or a dry powder formulation according to the invention, for use in the treatment of a patient suffering from malnutrition, weight loss and/or muscle atrophy.
  • the invention also relates to a powder formulation according to the invention in the manufacture of a medicament for the treatment of malnutrition, weight loss and/or muscle atrophy.
  • malnutrition under-nutrition
  • weight loss and muscle atrophy may be related in the sense that weight loss occurs because muscle are suffering from atrophy, but may also be unrelated.
  • Weight loss may occur independently of malnutrition but may be due to muscle atrophy that is the result of another disorder than malnutrition.
  • weight loss may not be completely due to loss of muscle loss, or muscle atrophy.
  • muscle atrophy may be the result of malnutrition, it may also be the result of non-use of muscles, not directly as a result of malnutrition, but for instance due to prolonged immobility.
  • muscle atrophy or weight loss may be unrelated to malnutrition but may be the result of another disorder/disease such as cancer or AIDS.
  • the nutritional compositions of the present invention may be administered for the treatment of malnutrition-related disorders such as muscle atrophy, whereas it may also be used in muscle atrophy treatment that is not directly caused by malnutrition. In either case, the administration of the nutritional compositions of the present invention results in muscle weight gain, and hence in weight gain and reverses muscle atrophy. Most preferably however, the nutritional compositions of the present invention are used in the treatment of malnutrition and malnutrition-related disorders.
  • the present invention relates to ursolic acid for use in the treatment of malnutrition, weight loss and/or muscle atrophy. And in another embodiment, the present invention relates to the use of ursolic acid in the manufacture of a medicament for the treatment of malnutrition, weight loss and/or muscle atrophy.
  • the present invention also relates to a method for the treatment of a mammalian subject suffering from malnutrition, weight loss and/or muscle atrophy, comprising the steps of administering a liquid or semi-liquid nutritional composition according to the invention to said mammalian subject; monitoring the rate of malnutrition of said mammalian subject, and/or the weight of said mammalian subject, and/or the rate of muscle atrophy in said mammalian subject; and optionally adjusting the amount of ursolic acid and/or a composition according to the invention to be administered.
  • the amount of administered ursolic acid or composition according to the invention may be altered, and preferably higher than initially administered, depending on the outcome of the assessment of the mammalian subject receiving the administration.
  • the mammalian subject as mentioned herein is preferably a human subject. It was calculated by the inventors of the present invention that the amounts of constituents, as exemplified in Table II should preferably be administered to the mammalian subject six times per day, which is therefore the preferred regimen.
  • the dosing volumes and intervals may be increased or decreased.
  • the nutritional composition of present invention further comprises carbohydrate in an amount from about 6 to about 20 grams per 100 Kcal of the composition, such as from about 7 to about 18.5, from about 8 to about 16, from about 9 to about 14.5, from about 10 to about 13, such as about 11 grams per 100 Kcal of the composition.
  • the composition according to the invention is a liquid or semi-liquid composition, it may comprise carbohydrate in an amount from about 150 to about 480 mg/ml, such as from about 160 to about 440 mg/ml, from about 170 to about 400 mg/ml, from about 180 to about 360 mg/ml, from about 190 to about 320 mg/ml, from about 200 to about 280 mg/ml, and preferably from about 210 to about 270 mg/ml.
  • Suitable carbohydrates used in the composition are monosaccharides, disaccharides, polysaccharides and oligosaccharides.
  • the carbohydrates are selected from maltodextrin and sugars, where suitable sugars may be glucose, fructose, sucrose, maltodextrins.
  • the composition of the present invention further comprises one or more fats in an amount from about 1.5 to about 5.5 grams per 100 Kcal of the composition, such as from about 2.5 to about 5.0, from about 3.5 to about 4.5, such as about 4.0 grams per 100 Kcal of the composition.
  • the composition according to the invention is a liquid or semi-liquid composition, it may comprise one or more fats in an amount of from about 40 to about 140 mg/ml, such as from about 52 to about 132 mg/ml, from about 64 to about 124 mg/ml, from about 76 to about 116 mg/ml, such as from about 88 to about 108 mg/ml, such as about 96 mg/ml.
  • Suitable fats are monounsaturated, polyunsaturated and saturated fats.
  • the one or more fats are selected from the group consisting of milk fat and vegetable oils.
  • the nutritional composition of present invention further comprises branched chain amino acids, leucine, isoleucine and valine in an amount from about 0.5 to about 3.0 grams per 100 Kcal of the composition, or from about 12 to about 72 mg/ml if the composition is a liquid or semi-liquid composition for leucine; from about 0.2 to about 2.0 grams per 100 Kcal of the composition or from about 4.8 to about 48 mg/ml if the composition is a liquid or semi-liquid composition for isoleucine; and from about from about 0.2 to about 2.0 grams per 100 Kcal of the composition or from about 4.8 to about 48 mg/ml if the composition is a liquid or semi-liquid composition for valine.
  • the amount of leucine is from about 0.75 to about 2.0, preferably about 1.0 grams per 100 Kcal of the composition, or, if the composition is a liquid or semi-liquid, from about 18 to about 48 mg/ml, preferably about 24.7 mg/ml.
  • the amount of isoleucine is from about 0.3 to about 1.0, preferably about 0.44 grams per 100 Kcal of the composition, or, if the composition is a liquid or semi-liquid from about 7.2 to about 24 mg/ml, preferably about 10.6 mg/ml.
  • the amount of isoleucine is from about 0.3 to about 1.0 l, preferably about 0.45 grams per 100 Kcal of the composition, or, if the composition is a liquid or semi-liquid from about 7.2 to about 24 mg/ml, preferably about 10.8 mg/ml.
  • the composition of the present invention further comprises Calcium, Chloride, Phosphorus, Iron, Iodine, Potassium, Copper, Magnesium, Manganese, Sodium, Selenium, Zinc, and/or salts thereof.
  • the composition further comprises Chromium, Molybdenum, and/or salts thereof.
  • the composition comprises Fluoride.
  • the composition comprises these elements in amounts complying with the regulations for compositions of medical nutrition, such as e.g. the Commission Directive 1999/21/EC of 25 Mar. 1999 in EU.
  • the composition of the present invention further comprises vitamin C, vitamin E, vitamin A, vitamin B3, vitamin D, pantothenic acid, vitamin K1, vitamin B1, vitamin B6, vitamin B2, folic acid, biotin and vitamin B12.
  • the composition comprises these vitamins in amounts complying with the regulations for compositions of medical nutrition, such as e.g. the Commission Directive 1999/21/EC of 25 Mar. 1999 in EU.
  • HMB leucine metabolites
  • glutamine glutamine
  • carnitine glutamine
  • beta-alanine carnosine
  • creatine bioactive peptides
  • omega-3 fatty acids such as EPA and DHA.
  • the different components of a nutritional composition according to the present invention can be varied within the given ranges for each component independently of one another. In certain situations an even more optimal effect can be achieved by choosing an optimum for a plurality of components in combination.
  • a liquid or semi-liquid nutritional composition comprising: 70 to 200 mg/ml dairy proteins; 30 to 60 ng/ml vitamin D or a derivative thereof; and 0.2 to 1 mg/ml ursolic acid; wherein the casein:whey ratio in said dairy proteins ranges from 20:80 to 80:20 and wherein 30 to 45% of the total amino acid content is a mixture of leucine, isoleucine and valine.
  • the casein:whey ratio is from about 30:70 to about 70:30, such as from about 40:60 to about 68:32, from about 45:55 to about 65:35, such as about 60:40.
  • a liquid or semi-liquid nutritional composition that comprise the ingredients with their respective concentrations as provided in Table II and further comprises 0.2 to 0.8 mg/ml ursolic acid. 13.
  • a powder formulation comprising dairy proteins; vitamine D or a derivative thereof; ursolic acid; and optionally an amino acid premix comprising free leucine, free isoleucine and free valine, in suitable amounts that when it is combined with a suitable carrier provides for a liquid or semi-liquid nutritional composition according to any of the preceding clauses.
  • a suitable carrier is water.
  • a suitable amount of carrier is from about 1.5 to about 3 ml per gram of powder formulation, such as from about 1.7 to about 2.8 ml per gram of powder formulation. 16.
  • a powder formulation according to any of clauses 13-15 wherein 100 grams of the powder comprises from about 300 to about 700 Kcal, such as, from about 350 to about 650 Kcal, from about 400 to about 600 Kcal or from about 450 to about 550 Kcal. 17.
  • a powder formulation comprising an amino acid premix comprising free leucine, free isoleucine and free valine; vitamine D or a derivative thereof; and ursolic acid; in suitable amounts that when it is combined with a dairy-protein containing product such as milk or yoghurt, provides for a liquid or semi-liquid nutritional composition according to any one of clauses 1-12. 18.
  • a nutritional composition comprising per 100 Kcal: from about 2.5 to about 8.5 grams dairy proteins; from about 1.2 to about 3.0 ⁇ g vitamin D or a derivative thereof; and from about 8 to about 50 mg ursolic acid; wherein the casein:whey ratio in said dairy proteins is from 20:80 to 80:20 and wherein 30 to 45% of the total amino acid content is a mixture of leucine, isoleucine and valine. 19.
  • 21. A nutritional composition according to any of clauses 18-20, wherein the composition is substantially free of other proteins besides casein and whey.
  • 22. A nutritional composition according to any of clauses 18-21, wherein the amount of dairy proteins is from about 3.0 to about 7.5, such as, from about 3.5 to about 6.5, from about 4.0 to about 6.0, or from about 4.5 to about 5.5, such as about 5.0 grams per 100 Kcal of composition. 23.
  • a nutritional composition according to any of clauses 18-21 wherein the amount of ursolic acid is from about 15 to about 48, such as, from about 20 to about 46, from about 25 to about 44, from about 30 to about 40 or about 35 mg per 100 Kcal of composition.
  • 24. A nutritional composition according to any of clauses 18-23, comprising valine and isoleucine in an amount of 7 to 10% of the total amino acid content and leucine in an amount of 16 to 25% of the total amino acid content, and wherein valine, isoleucine and leucine are present in free and bound form. 25.
  • 26. A nutritional composition according to any of clauses 18-25, wherein the composition is a powder.
  • 27. A liquid or semi-liquid nutritional composition according to any one of clauses 1-12, a powder formulation according to any one of clauses 13-17 or a nutritional composition according to any one of clauses 18-26, for use in the treatment of a patient suffering from malnutrition, weight loss and/or muscle atrophy. 28.
  • 31. A composition or formulation according to any of clauses 27-30, wherein the liquid or semi-liquid nutritional composition is in a dosage of about 200 to about 500 Kcal, such as of about 250 to about 350 Kcal, such as, about 300 Kcal. 32.
  • 33. Use of a liquid or semi-liquid nutritional composition according to any one of clauses 1-12, a powder formulation according to any one of clauses 13-17 or a nutritional composition according to any one of claims 18 - 26 , for treating, preventing or reducing malnutrition, weight loss and/or muscle atrophy in a mammalian subject.
  • 34. Use according to claim 33 , wherein the mammalian subject is a human. 35.
  • composition or formulation is administered in a dosage of about 1/7 to about 1 ⁇ 5 of the daily energy intake of the subject.
  • composition or formulation is administered in a dosage of about 1 ⁇ 6 of the daily energy intake of the subject.
  • composition or formulation is administered in a dosage comprising about 200 to about 500 Kcal, such as, of about 250 to about 350 Kcal, such as, about 300 Kcal. 38.
  • composition or formulation is administered nutritional composition is liquid or semi-liquid and is administered in a dosage of about 100 to about 300 ml, such as, of about 150 to about 250 ml, such as, about 200 ml.
  • composition or formulation is administered in at least one time per day, such as, at least two times, at least three times, at least four times, at least 5 times or at least six times per day. 40.
  • Method for treatment, prevention and/or reduction of malnutrition, weight loss and/or muscle atrophy in a mammalian subject comprising administering a liquid or semi-liquid nutritional composition according to any one of clauses 1-12, a powder formulation according to any one of clauses 13-17 or a nutritional composition according to any one of claims 18 - 26 , to said subject.
  • a liquid or semi-liquid nutritional composition according to any one of clauses 1-12, a powder formulation according to any one of clauses 13-17 or a nutritional composition according to any one of claims 18 - 26 , to said subject.
  • composition or formulation is administered in a dosage comprising about 200 to about 500 Kcal, such as, of about 250 to about 350 Kcal, such as, about 300 Kcal. 45.
  • composition or formulation is administered nutritional composition is liquid or semi-liquid and is administered in a dosage of about 100 to about 300 ml, such as, of about 150 to about 250 ml, such as, about 200 ml. 46.
  • composition or formulation is administered in at least one time per day, such as, at least two times, at least three times, at least four times, at least 5 times or at least six times per day.
  • the aim of this study was to establish conditions for nutritional weight gain products in order to assess the effects of a novel nutritional composition with respect to weight gain and body composition, in the context of metabolic organ health and low-grade inflammation.
  • the design of the study is shown in FIG. 1 .
  • a standard chow rodent diet (R/M Sniff® standard) was used as the basic food and sufficient water was provided ad libitum throughout the entire experiment.
  • mice Prior to the start of the experiment, all mice were acclimatized for two weeks during which their food intake of standard rodent diet (100% chow) was determined individually per mouse.
  • the caloric restriction and refeeding regimen was based on Gallardo et al. (Gallardo C M. et al. 2014. Behavioral and neural correlates of acute and scheduled hunger in C57BL/6 mice. Plos One 9(5):1-12) and Williams et al. (Williams T D. et al. 2002. Cardiovascular responses to caloric restriction and thermoneutrality in C57BL/6J mice. Am J Physiol Regulatory Integrative Comp Physiol 282:R1459-R1467) who showed a rapid decline in body weight and subsequent stabilization within 14 to 21 days. Nutridrink CP is a nutritionally complete, and commercially available medical food sold by Nutricia, the Netherlands. Nutricia is a company wholly owned by Danone. Essentially the same product is also sold under the name Fortisip Compact Protein. The version that was used in this example contains 240 kcal per 100 ml with the characteristics as shown in Table I.
  • the macronutrient composition as well as the caloric value of the test compounds according to the present invention differ from Nutridrink CP that contains 14.4 g/100 ml total dairy protein comprising a casein:whey ratio of approximately 93:7. As noted above, for each Group 5, and 6, equal amounts of protein (in grams) were administered. Nutridrink CP was handled as recommended by the manufacturer. Vital01 was prepared by adding 35 mg ursolic acid to 100 ml Vital00, the content of which is provided in Table II.
  • the animals were monitored daily by Echo-MRI (which was performed according to the manufacturer's instructions, EchoMRI LLC, Houston, USA). Body weight and food intake as well as intake of the weight gain products were determined daily. Upon sacrifice, muscles (gastrocnemius, quadriceps, tibialis and soleus) of both hind limbs were collected and muscle weights were determined. Following weighing of muscles from both the right and left hind limbs, one gastrocnemius, one quadriceps, one tibialis and one soleus muscle was fixed in formaldehyde and embedded in paraffin (for histology purposes).
  • the gastrocnemius, quadriceps, tibialis and soleus muscle from the other hind leg was snap-frozen and stored at ⁇ 80° C. for future RNA analysis. Also the liver was isolated, weighed and stored at ⁇ 80° C. Plasma was collected by heart puncture. All procedures were standard, in accordance with protocols and guidelines that were prior approved by the Animal Ethics Committee, and performed using general methodology known to the person skilled in the art.
  • mice were stratified in three groups of 10, and the 60% chow diets were supplemented with either standard chow, Nutridrink CP, or with Vital01 according to the following calculation:
  • mice were fed with standard chow to 100% of a regular mouse diet (which is approximately 5 g/day). Hence, 40% (generally about 2 g) additional chow was provided to the mice in control Group 3.
  • the choice for normalizing the protein content was based on the fact that the primary objective of this experiment was to compare the effects of ursolic acid and the different casein/whey ratios of Nutridrink CP and Vital01 on weight gain, and in particular gain of muscle mass which is mainly a result of protein uptake and synthesis and not fat accumulation or energy intake.
  • mice in Groups 3-6 were held on a 60 kcal % diet as compared to the two weeks preceding the food restriction period and lost in average 5-6 grams in total body weight ( ⁇ 23%). Upon refeeding according to the schedules discussed above, the mice started to gain weight almost instantly, see FIG. 3 .
  • the control Group 4 that received their normal 100 kcal % diet as before the starvation period gained weight relatively slowly. Unexpectedly, animals in the group receiving Vital01 (Group 6), displayed a very rapid increase in total body weight that was significantly higher than the group that received Nutridrink CP (Group 5).
  • FIG. 4 shows the increase in lean body mass, wherein also the Vital01 group showed a faster increase than the Nutridrink CP and control Group (that displayed a comparable increase in lean body mass). It is concluded that the Vital01 composition caused a significant faster increase in total body weight as well as in lean body mass in mammalian subjects that suffered from a decreased body weight after two weeks of starvation on a 60 kcal % diet. Due to the surprisingly fast increase in bodyweight as observed for the Vital01 group, the study was ended sooner than anticipated by sacrificing the animals already on day 6 of the refeeding phase.
  • FIG. 5 shows the weight of the quadriceps muscle at sacrifice. Although in the relatively short period of refeeding, the weight of the quadriceps did not reach baseline values as were determined in the reference group (Group 1), all groups that received refeeding did clearly build up the quadriceps muscle in comparison to non-refed animals in Group 3. Also, it shows that the Vital01 group reached a quadriceps mass that was higher than the control Group 4 (100 kcal % chow) and Group 5 (Nutridrink CP).
  • FIG. 6 shows the increase in the gastrocnemius mass.
  • FIG. 8 shows the mass of the tibialis, and similar to the soleus muscle, the tibialis shows a relatively modest atrophy upon starvation when compared to the quadriceps and gastrocnemius muscles. Still, it appears that refeeding with the Vital01 composition resulted in a more or less normal tibialis mass, while both the control group with 100 kcal % chow (Group 4) and Nutridrink CP (Group 5) were trailing behind.
  • FIG. 9 shows that no difference was observed between the different refed groups, although there was a clear decrease in liver mass upon starvation (Group 3 (second bar) compared to Group 1 (first bar)) that was reversed in all refeeding groups.
  • Nutridrink CP and Vital01 were both provided as liquid formulations which, due to low volumes and spillage, could not be administered to the mice in their regular drinking bottles. To this end, and to accurately monitor and control intake of test products, both Nutridrink CP and Vital01 were ‘gellified’ by the addition of the non-metabolizable hydroxypropyl methylcellulose to form a semi-solid gel that could readily be fed to the animals in a petridish.
  • the daily volume of gellified Nutridrink CP and Vital01 that mice received was 3.3 ml Nutridrink CP or 4.9 ml Vital01. 100% chow corresponds to approximately 5 g dry weight, and mice in all groups were provided with water ad lib.
  • ursolic acid has an extremely low bioavailability.
  • a study investigating the intestinal uptake of ursolic acid found that a dose of 80 mg/kg bodyweight ursolic acid had an oral bioavailability of only 0.6% (Liao Q, et al. 2005, LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. Yakugaku Zasshi 125(6):509-515).
  • Others have been unable to detect ursolic acid in blood or tissues upon oral administration, despite observing clear physiological or pharmacological responses to ursolic acid. This may have been due to the low bioavailability and/or by the lack of sensitive methods to measure ursolic acid levels in situ.
  • ursolic acid was actually taken up in the context of Vital01
  • a highly sensitive analytical method was developed to measure ursolic acid in the small volumes of plasma that were obtained from sacrificed animals in the weight gain experiment.
  • a highly sensitive UPLC-MS was used, essentially as described by Xia et al. (Quantitation of ursolic acid in human plasma by ultra-performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study. J Chromatography 2011 879(2):219-224), albeit with significant modifications to enable analysis of small volume samples of mouse or human plasma. Since conversion of ursolic acid into its isomer oleanolic acid has been described to occur in animal studies, the method was further modified to simultaneously measure both ursolic acid and oleanolic acid.
  • ursolic acid was readily detectable in plasma samples taken from animals refed with Vital01 (Group 6), with an average concentration of 76.6 ⁇ 8.8 ng/ml. Given that the animals (in all groups) had finished all of their food in the morning, and that they were sacrificed in the afternoon without intermittent feeding, suggests that formulation of ursolic acid in Vital01 significantly increases its bioavailability. This may have been facilitated by increased solubilization of ursolic acid through fats and lipids which are present in the composition of the present invention and/or possibly by complexing to proteins or amino acids in Vital01 to facilitate and enhance its transport over the gut wall.
  • Study population Elderly subjects ( ⁇ 65 y) with malnutrition or risk for malnourishment as assessed by the MNA (mini nutritional assessment).
  • Main study parameters/endpoints The main interest is in the mean differences in change in body weight (kg) and lean body mass (kg) between treatment 1 vs. treatment 2. Furthermore, physical performance, muscle health and immune function are assessed.
  • Vital02 comprises 465.02 Kcal per 100 g of powder composition.
  • Table IV gives the composition of the Vital02 powder, which is used for the preparation of a liquid composition administered to the subjects.
  • Table V gives the total amino acid content of Vital02, from which the percentage of Isoleucine, Valine and Leucine of the total amino acid content can be derived.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US15/738,215 2015-06-25 2016-06-24 Compositions and methods for the treatment of malnutrition Abandoned US20180169187A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/906,541 US11419915B2 (en) 2015-06-25 2020-06-19 Compositions and methods for the treatment of malnutrition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2015032 2015-06-25
NL2015032A NL2015032B1 (en) 2015-06-26 2015-06-26 Compositions and methods for the treatment of malnutrition.
PCT/EP2016/064636 WO2016207329A1 (en) 2015-06-26 2016-06-24 Compositions and methods for the treatment of malnutrition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/064636 A-371-Of-International WO2016207329A1 (en) 2015-06-25 2016-06-24 Compositions and methods for the treatment of malnutrition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/906,541 Division US11419915B2 (en) 2015-06-25 2020-06-19 Compositions and methods for the treatment of malnutrition

Publications (1)

Publication Number Publication Date
US20180169187A1 true US20180169187A1 (en) 2018-06-21

Family

ID=56345097

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/738,215 Abandoned US20180169187A1 (en) 2015-06-25 2016-06-24 Compositions and methods for the treatment of malnutrition
US16/906,541 Active US11419915B2 (en) 2015-06-25 2020-06-19 Compositions and methods for the treatment of malnutrition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/906,541 Active US11419915B2 (en) 2015-06-25 2020-06-19 Compositions and methods for the treatment of malnutrition

Country Status (12)

Country Link
US (2) US20180169187A1 (de)
EP (1) EP3313207B1 (de)
JP (1) JP6851086B2 (de)
CN (1) CN107809916A (de)
AU (1) AU2016282923B2 (de)
BR (1) BR112017027636B1 (de)
CA (1) CA2987364C (de)
DK (1) DK3313207T3 (de)
ES (1) ES2775610T3 (de)
NL (1) NL2015032B1 (de)
PL (1) PL3313207T3 (de)
WO (1) WO2016207329A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115736259A (zh) * 2022-11-30 2023-03-07 内蒙古伊利实业集团股份有限公司 可改善肌肉力量的组合物及其在食品中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2015032B1 (en) 2015-06-26 2017-01-24 Vitalnext B V Compositions and methods for the treatment of malnutrition.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229029A1 (en) * 2002-06-06 2003-12-11 Charles Laudadio Cardiac glycosides for treating muscle pain and spasm
WO2012005568A1 (en) * 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
US20130203712A1 (en) * 2010-05-20 2013-08-08 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405193B2 (en) 2000-05-31 2008-07-29 Serono Genetics Institute S.A. Use of Acrp30 globular head to promote increases in muscle mass and muscle differentiation
PT1638414E (pt) * 2003-06-23 2009-07-13 Nestec Sa Fórmula para lactentes ou fórmula de transição
US8021701B1 (en) 2005-04-13 2011-09-20 Perry Stephen C Composition to retard the onset of symptoms of alzheimer's disease
MX2010012171A (es) 2008-05-21 2010-11-30 Stokely Van Camp Inc Bebida de recupercion a base de leche.
CN102210837A (zh) * 2010-04-09 2011-10-12 肖嘉惠 治疗艾滋病的药物
CN103458891A (zh) * 2011-04-13 2013-12-18 味之素株式会社 营养组合物
US20140037604A1 (en) * 2011-04-18 2014-02-06 Nestec S.A. Nutritional compositions comprising alpha-hydroxyisocaproic acid
CA2838275C (en) 2011-06-06 2021-08-10 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
PL2833724T3 (pl) 2012-04-04 2020-04-30 Société des Produits Nestlé S.A. Trwałe w warunkach otoczenia zakwaszone produkty pochodzenia mlecznego albo mlecznopodobne oraz sposoby ich wytwarzania
MX367861B (es) * 2012-10-04 2019-09-09 Abbott Lab Una composición nutricional para usarse en la preservación del músculo esquelético.
WO2014099904A1 (en) * 2012-12-17 2014-06-26 Abbott Laboratories Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject
US20150164833A1 (en) * 2013-12-17 2015-06-18 Mead Johnson Nutrition Company Nutritional composition containing a neurologic component of ursolic acid and uses thereof
NL2015032B1 (en) 2015-06-26 2017-01-24 Vitalnext B V Compositions and methods for the treatment of malnutrition.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229029A1 (en) * 2002-06-06 2003-12-11 Charles Laudadio Cardiac glycosides for treating muscle pain and spasm
US20130203712A1 (en) * 2010-05-20 2013-08-08 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
WO2012005568A1 (en) * 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115736259A (zh) * 2022-11-30 2023-03-07 内蒙古伊利实业集团股份有限公司 可改善肌肉力量的组合物及其在食品中的应用

Also Published As

Publication number Publication date
US11419915B2 (en) 2022-08-23
NL2015032B1 (en) 2017-01-24
JP2018519365A (ja) 2018-07-19
EP3313207A1 (de) 2018-05-02
AU2016282923B2 (en) 2019-10-17
AU2016282923A1 (en) 2017-12-14
CA2987364C (en) 2023-09-26
ES2775610T3 (es) 2020-07-27
EP3313207B1 (de) 2019-12-11
BR112017027636A2 (pt) 2018-08-28
JP6851086B2 (ja) 2021-03-31
PL3313207T3 (pl) 2020-06-01
CA2987364A1 (en) 2016-12-29
WO2016207329A1 (en) 2016-12-29
US20200316170A1 (en) 2020-10-08
CN107809916A (zh) 2018-03-16
BR112017027636B1 (pt) 2022-04-12
DK3313207T3 (en) 2020-03-02

Similar Documents

Publication Publication Date Title
US10136669B2 (en) Method for decreasing visceral fat or increasing energy consumption
US8703209B2 (en) Composition and method for modulating hydrogen ion physiology
JP2008534599A (ja) 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
CA2903561C (en) Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
US11419915B2 (en) Compositions and methods for the treatment of malnutrition
Rondanelli et al. A food pyramid for adult patients with phenylketonuria and a systematic review on the current evidences regarding the optimal dietary treatment of adult patients with PKU
US20220117943A1 (en) Formulations for personalized methods of treatment
TW201141466A (en) Methods of modulating inflammation in preterm infants using carotenoids
RU2335927C2 (ru) Обогащенные лейцином питательные композиции
WO2018085440A1 (en) Reduction and prevention of muscle loss by conjugated linoleic acid (cla) and vitamin d
US20210113501A1 (en) Method of administering beta-hydroxy-beta-methylbutyrate (hmb)
Bales et al. Redefining nutritional frailty: Interventions for weight loss due to undernutrition
WO2014144022A1 (en) Low calorie infant formula containing
WO2023222706A1 (en) Compositions comprising a combination of creatine and oleuropein or a metabolite thereof and their use for improving muscle function
WO2020210448A1 (en) Composition for stimulating muscle growth, repair, and maintenance
Diane Boomsma PharmD The Magic of Magnesium

Legal Events

Date Code Title Description
AS Assignment

Owner name: VITALNEXT B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZONDAG, GERBEN CAROLUS MARTINUS;STRIJKER, REINDER;REEL/FRAME:044727/0439

Effective date: 20180123

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION